Piper Jaffray Downgrades Ardea Biosciences To Neutral, PT To $30

January 31, 2011 7:16 AM | 8 seconds read |
Piper Jaffray has downgraded Ardea Biosciences, Inc. RDEA from Overweight to Neutral and has lowered the price target from $34 to $30.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: DowngradesPrice TargetAnalyst RatingsArdea BiosciencesHealth CarePharmaceuticalsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!